I watch IDRA because their pipeline is somewhat similar to CTIX, but not as strong of course. Their oncology drug's potential is nowhere near K, their psoriasis drug P2 result isn't that impressive, and they don't have an antibiotic pipeline. Yet their market cap is $500M, go figure.

Hoping to get the K top-line data before SH meeting next Tuesday.

Quote:

---

So if they're up 13% on that data, what do you think will happen when/if Kevetrin data is better than that?

---